#BEGIN_DRUGCARD DB00042

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Though pharmacokinetic or ADME studies were not performed, Botulinum Toxin Type B is not expected to be present in the peripheral blood at measurable levels following IM injection at the recommended doses.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Myobloc (Solstice Neurosciences)
Neurobloc (Solstice Neurosciences)

# CAS_Registry_Number:
93384-44-2

# ChEBI_ID:
Not Available

# Chemical_Formula:
Not Available

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
>Botulinum neurotoxin type B - Clostridium botulinum
MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFN
KSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLG
DRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNH
FASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLY
GIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIV
DRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETN
IAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQA
YEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSN
YIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQY
LYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVND
FVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLI
PVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMY
KALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSV
SYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDL
SIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFK
LTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNS
GWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYING
KLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSY
SEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLY
IGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISD
SDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCIS
KWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
75108

# Description:
Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.

# Dosage_Forms:
Injection, solution	Intramuscular

# Drug_Category:
Antidystonic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
10534247	Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8.
15839401	Shukla HD, Sharma SK: Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8.
15887434	Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc. 2005 May;80(5):657-66.
15907915	Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9.
15928517	Schurch B, Corcos J: Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 2005 Jul;15(4):264-7.

# Drug_Type:
Approved
Biotech

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
M81186

# Generic_Name:
Botulinum Toxin Type B

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D02735

# LIMS_Drug_ID:
42

# Mechanism_Of_Action:
Botulinum Toxin Type B binds to and cleaves the synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin) which is a component of the protein complex responsible for docking and fusion of the synaptic vesicle to the presynaptic membrane, a necessary step to neurotransmitter release.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
150804.0000

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1F82

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164747061

# Pharmacology:
Botulinum Toxin Type B inhibits acetylcholine release at the neuromuscular junction via a three stage process: 1) Heavy Chain mediated neurospecific binding of the toxin, 2) internalization of the toxin by receptor-mediated endocytosis, and 3) ATP and pH dependent translocation of the Light Chain to the neuronal cytosol where it acts as a zinc-dependent endoprotease cleaving polypeptides essential for neurotransmitter release.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB00042

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/botulinumtoxin.htm

# Salts:
Not Available

# Secondary_Accession_No:
BIOD00070
BTD00070

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
liquid

# Structure:
0

# SwissProt_ID:
P10844

# SwissProt_Name:
BXB_CLOBO

# Synonyms:
BTX-B
Botulinum neurotoxin type B precursor

# Synthesis_Reference:
Not Available

# Toxicity:
One unit of Botulinum Toxin Type B corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice.

# Update_Date:
2010-09-29 14:34:47 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Botulinum_toxin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic vesicle

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
14573702	Liu W, Montana V, Chapman ER, Mohideen U, Parpura V: Botulinum toxin type B micromechanosensor. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13621-5. Epub 2003 Oct 22.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
VAMP2

# Drug_Target_1_GenBank_ID_Gene:
M36205

# Drug_Target_1_GenBank_ID_Protein:
338632

# Drug_Target_1_GeneCard_ID:
VAMP2

# Drug_Target_1_Gene_Name:
VAMP2

# Drug_Target_1_Gene_Sequence:
>351 bp
ATGTCTGCTACCGCTGCCACGGCCCCCCCTGCTGCCCCGGCTGGGGAGGGTGGTCCCCCT
GCACCCCCTCCAAACCTCACCAGTAACAGGAGACTGCAGCAGACCCAGGCCCAGGTGGAT
GAGGTGGTGGACATCATGAGGGTGAACGTGGACAAGGTCCTGGAGCGAGACCAGAAGCTG
TCGGAGCTGGACGACCGTGCAGATGCACTCCAGGCGGGGGCCTCCCAGTTTGAAACAAGC
GCAGCCAAGCTCAAGCGCAAATACTGGTGGAAAAACCTCAAGATGATGATCATCTTGGGA
GTGATTTGCGCCATCATCCTCATCATCATCATAGTTTACTTCAGCTCTTAA

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
10932255	Hanson MA, Stevens RC: Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution. Nat Struct Biol. 2000 Aug;7(8):687-92.
1976629	Archer BT 3rd, Ozcelik T, Jahn R, Francke U, Sudhof TC: Structures and chromosomal localizations of two human genes encoding synaptobrevins 1 and 2. J Biol Chem. 1990 Oct 5;265(28):17267-73.
7835332	Kutay U, Ahnert-Hilger G, Hartmann E, Wiedenmann B, Rapoport TA: Transport route for synaptobrevin via a novel pathway of insertion into the endoplasmic reticulum membrane. EMBO J. 1995 Jan 16;14(2):217-23.
8760387	Jagadish MN, Fernandez CS, Hewish DR, Macaulay SL, Gough KH, Grusovin J, Verkuylen A, Cosgrove L, Alafaci A, Frenkel MJ, Ward CW: Insulin-responsive tissues contain the core complex protein SNAP-25 (synaptosomal-associated protein 25) A and B isoforms in addition to syntaxin 4 and synaptobrevins 1 and 2. Biochem J. 1996 Aug 1;317 ( Pt 3):945-54.

# Drug_Target_1_HGNC_ID:
HGNC:12643

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3860

# Drug_Target_1_Locus:
17p13.1

# Drug_Target_1_Molecular_Weight:
12649

# Drug_Target_1_Name:
Vesicle-associated membrane protein 2

# Drug_Target_1_Number_of_Residues:
116

# Drug_Target_1_PDB_ID:
1SFC

# Drug_Target_1_Pathway:
Cimetidine Pathway	SMP00232
Esomeprazole Pathway	SMP00225
Famotidine Pathway	SMP00231
Lansoprazole Pathway	SMP00227
Nizatidine Pathway	SMP00233
Omeprazole Pathway	SMP00226
Pantoprazole Pathway	SMP00228
Pirenzepine Pathway	SMP00246
Rabeprazole Pathway	SMP00229
Ranitidine Pathway	SMP00230

# Drug_Target_1_Pfam_Domain_Function:
PF00957	Synaptobrevin

# Drug_Target_1_Protein_Sequence:
>Vesicle-associated membrane protein 2
MSATAATAPPAAPAGEGGPPAPPPNLTSNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKL
SELDDRADALQAGASQFETSAAKLKRKYWWKNLKMMIILGVICAIILIIIIVYFSS

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Involved in the targeting and/or fusion of transport vesicles to their target membrane

# Drug_Target_1_SwissProt_ID:
P63027

# Drug_Target_1_SwissProt_Name:
VAMP2_HUMAN

# Drug_Target_1_Synonyms:
Synaptobrevin-2
VAMP-2

# Drug_Target_1_Theoretical_pI:
8.48

# Drug_Target_1_Transmembrane_Regions:
95-114

# Drug_Target_2_Cellular_Location:
Cytoplasmic vesicle

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
VAMP1

# Drug_Target_2_GenBank_ID_Gene:
M36200

# Drug_Target_2_GenBank_ID_Protein:
338625

# Drug_Target_2_GeneCard_ID:
VAMP1

# Drug_Target_2_Gene_Name:
VAMP1

# Drug_Target_2_Gene_Sequence:
>357 bp
ATGTCTGCTCCAGCTCAGCCACCTGCTGAAGGGACAGAAGGGACTGCCCCAGGTGGGGGT
CCCCCTGGCCCTCCTCCTAACATGACCAGTAACAGACGACTACAGCAAACCCAGGCACAA
GTGGAGGAGGTGGTGGACATCATACGTGTGAACGTGGACAAGGTCCTGGAGAGGGACCAG
AAGCTGTCAGAGCTGGATGACCGAGCTGATGCCTTGCAGGCAGGAGCATCACAATTTGAG
AGCAGTGCTGCCAAGCTAAAGAGGAAGTATTGGTGGAAAAACTGCAAGATGATGATCATG
CTGGGAGCCATCTGTGCCATCATCGTGGTAGTTATTGTAATCTACTTTTTTACTTGA

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
1976629	Archer BT 3rd, Ozcelik T, Jahn R, Francke U, Sudhof TC: Structures and chromosomal localizations of two human genes encoding synaptobrevins 1 and 2. J Biol Chem. 1990 Oct 5;265(28):17267-73.
8760387	Jagadish MN, Fernandez CS, Hewish DR, Macaulay SL, Gough KH, Grusovin J, Verkuylen A, Cosgrove L, Alafaci A, Frenkel MJ, Ward CW: Insulin-responsive tissues contain the core complex protein SNAP-25 (synaptosomal-associated protein 25) A and B isoforms in addition to syntaxin 4 and synaptobrevins 1 and 2. Biochem J. 1996 Aug 1;317 ( Pt 3):945-54.
9658161	Isenmann S, Khew-Goodall Y, Gamble J, Vadas M, Wattenberg BW: A splice-isoform of vesicle-associated membrane protein-1 (VAMP-1) contains a mitochondrial targeting signal. Mol Biol Cell. 1998 Jul;9(7):1649-60.

# Drug_Target_2_HGNC_ID:
HGNC:12642

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3859

# Drug_Target_2_Locus:
12p

# Drug_Target_2_Molecular_Weight:
12902

# Drug_Target_2_Name:
Vesicle-associated membrane protein 1

# Drug_Target_2_Number_of_Residues:
118

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00957	Synaptobrevin

# Drug_Target_2_Protein_Sequence:
>Vesicle-associated membrane protein 1
MSAPAQPPAEGTEGTAPGGGPPGPPPNMTSNRRLQQTQAQVEEVVDIIRVNVDKVLERDQ
KLSELDDRADALQAGASQFESSAAKLKRKYWWKNCKMMIMLGAICAIIVVVIVIYFFT

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Involved in the targeting and/or fusion of transport vesicles to their target membrane

# Drug_Target_2_SwissProt_ID:
P23763

# Drug_Target_2_SwissProt_Name:
VAMP1_HUMAN

# Drug_Target_2_Synonyms:
Synaptobrevin-1
VAMP-1

# Drug_Target_2_Theoretical_pI:
6.59

# Drug_Target_2_Transmembrane_Regions:
97-116

# Drug_Target_3_Cellular_Location:
Cytoplasmic vesicle

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
19576489	Poulain B, Lonchamp E, Jover E, Popoff MR, Molgo J: [Mechanisms of action of botulinum toxins and neurotoxins] Ann Dermatol Venereol. 2009 May;136 Suppl 4:S73-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
SYT2

# Drug_Target_3_GenBank_ID_Gene:
AK090672

# Drug_Target_3_GenBank_ID_Protein:
21748879

# Drug_Target_3_GeneCard_ID:
SYT2

# Drug_Target_3_Gene_Name:
SYT2

# Drug_Target_3_Gene_Sequence:
>1260 bp
ATGAGGAACATTTTCAAGAGGAACCAGGAGCCTATTGTGGCTCCTGCCACCACCACCGCC
ACGATGCCCATTGGACCCGTGGACAACTCCACTGAGAGTGGGGGTGCTGGGGAGAGTCAG
GAGGACATGTTTGCCAAACTGAAGGAGAAGTTATTCAATGAGATAAACAAGATTCCCTTA
CCACCCTGGGCACTGATCGCCATTGCTGTGGTTGCTGGGCTCCTGCTTCTCACCTGCTGC
TTCTGCATCTGCAAGAAATGCTGCTGCAAGAAGAAGAAGAACAAGAAGGAGAAGGGCAAA
GGCATGAAGAATGCCATGAACATGAAGGACATGAAAGGGGGTCAGGATGACGACGACGCA
GAGACAGGCCTGACTGAGGGGGAAGGTGAAGGGGAGGAGGAGAAAGAGCCAGAGAACCTG
GGCAAACTGCAGTTTTCCCTGGACTATGATTTTCAGGCTAATCAGCTTACTGTGGGCGTT
CTGCAGGCTGCTGAACTGCCTGCCCTGGACATGGGAGGCACCTCAGACCCTTATGTCAAG
GTCTTCCTCCTTCCTGACAAGAAGAAGAAATATGAGACCAAAGTCCATCGGAAGACACTG
AACCCTGCCTTCAATGAAACCTTCACCTTCAAGGTGCCATACCAGGAGCTTGGGGGCAAA
ACTCTGGTGATGGCCATCTATGACTTTGACCGCTTCTCCAAACATGACATCATTGGAGAG
GTAAAGGTGCCTATGAACACAGTGGACCTCGGCCAGCCCATTGAGGAGTGGAGAGACCTG
CAAGGCGGGGAAAAGGAGGAGCCGGAGAAGCTGGGCGACATCTGCACCTCCCTGCGCTAT
GTGCCCACGGCCGGGAAGCTCACTGTCTGCATCCTGGAGGCTAAGAACCTCAAGAAGATG
GACGTGGGCGGCCTTTCAGACCCGTACGTGAAGATCCACCTGATGCAGAATGGCAAGAGG
CTCAAGAAGAAGAAGACAACCGTGAAGAAGAAGACCCTGAACCCATACTTCAACGAGTCC
TTCAGCTTTGAGATCCCCTTCGAGCAGATTCAGAAAGTCCAGGTAGTGGTCACCGTGCTG
GACTATGACAAGCTGGGCAAGAACGAAGCCATAGGCAAGATCTTCGTGGGCAGCAATGCC
ACGGGCACAGAGCTGCGGCACTGGTCCGACATGCTGGCCAACCCCCGGAGGCCCATCGCC
CAGTGGCACTCGCTCAAGCCTGAGGAGGAGGTGGATGCACTCCTGGGCAAGAACAAGTAG

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
Not Available

# Drug_Target_3_HGNC_ID:
HGNC:11510

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
3861

# Drug_Target_3_Locus:
1q32.1

# Drug_Target_3_Molecular_Weight:
46873

# Drug_Target_3_Name:
Synaptotagmin-2

# Drug_Target_3_Number_of_Residues:
419

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00168	C2

# Drug_Target_3_Protein_Sequence:
>Synaptotagmin-2
MRNIFKRNQEPIVAPATTTATMPIGPVDNSTESGGAGESQEDMFAKLKEKLFNEINKIPL
PPWALIAIAVVAGLLLLTCCFCICKKCCCKKKKNKKEKGKGMKNAMNMKDMKGGQDDDDA
ETGLTEGEGEGEEEKEPENLGKLQFSLDYDFQANQLTVGVLQAAELPALDMGGTSDPYVK
VFLLPDKKKKYETKVHRKTLNPAFNETFTFKVPYQELGGKTLVMAIYDFDRFSKHDIIGE
VKVPMNTVDLGQPIEEWRDLQGGEKEEPEKLGDICTSLRYVPTAGKLTVCILEAKNLKKM
DVGGLSDPYVKIHLMQNGKRLKKKKTTVKKKTLNPYFNESFSFEIPFEQIQKVQVVVTVL
DYDKLGKNEAIGKIFVGSNATGTELRHWSDMLANPRRPIAQWHSLKPEEEVDALLGKNK

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
May have a regulatory role in the membrane interactions during trafficking of synaptic vesicles at the active zone of the synapse. It binds acidic phospholipids with a specificity that requires the presence of both an acidic head group and a diacyl backbone

# Drug_Target_3_SwissProt_ID:
Q8N9I0

# Drug_Target_3_SwissProt_Name:
SYT2_HUMAN

# Drug_Target_3_Synonyms:
Synaptotagmin II
SytII

# Drug_Target_3_Theoretical_pI:
8.12

# Drug_Target_3_Transmembrane_Regions:
63-83

#END_DRUGCARD DB00042
